PLSE — Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Company profile
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: US
- Exchange: NASDAQ
- Employees: 75
- Website: https://www.pulsebiosciences.com
Latest SEC filings for PLSE
- 424B5 — 2026-09-15
- 8-K — 2026-09-15
- 8-K — 2026-09-15
- 424B5 — 2026-09-15
- 424B5 — 2026-08-06
- 8-K — 2026-08-06
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- 424B5 — 2026-08-06
- 8-K — 2026-07-29
Latest PLSE news
- — Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center (businesswire.com)
- — Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 (businesswire.com)
- — Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
- — Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20
Educational tool only — not investment advice.